Tiziana Life Sciences Completes Enrollment in Phase 2 Intranasal Foralumab MS Trial
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).
On May 21, 2026, Tiziana Life Sciences reported completion of patient enrollment in its INFORM-MS study, a randomized, double-blind, placebo-controlled Phase 2a trial of intranasal foralumab in non-active secondary progressive multiple sclerosis. The multicenter U.S. trial has enrolled 48 patients who will receive two dose levels or placebo over 12 weeks, followed by a six-month open-label extension to assess long-term safety and sustained benefit.
The INFORM-MS trial is described as the first placebo-controlled Phase 2 study of intranasal foralumab, and includes PET imaging for microglial activation, MRI and biomarker assessments to probe its immune-modulating effects. Topline data are expected in late third quarter 2026 and are slated to be presented at the ACTRIMS-ECTRIMS joint meeting in Toronto in October, a timeline that could influence Tiziana’s positioning in the multiple sclerosis space if results support a new, non-invasive treatment approach for na-SPMS.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing immunotherapy-based treatments using alternative drug delivery technologies, particularly intranasal administration. Its lead asset is intranasal foralumab, a fully human anti-CD3 monoclonal antibody positioned for neuroinflammatory and neurodegenerative diseases, with a pipeline supported by patented delivery platforms.
Average Trading Volume: 155,253
Technical Sentiment Signal: Strong Buy
Current Market Cap: $191.4M
For detailed information about TLSA stock, go to TipRanks’ Stock Analysis page.
